Background: Blood coagulation factor XIII (FXIII) is a zymogen that is transformed into an active transglutaminase by thrombin and Ca 2؉ . FXIII plays an essential role in fibrin stabilization and in the protection of fibrin from proteolytic degradation. No convenient method has been available for the measurement of FXIII activity in plasma. The aim of the present study was to improve and optimize a kinetic photometric FXIII assay originally developed in our laboratory. Methods: In the assay, FXIII was activated by thrombin and Ca 2؉ . Fibrin polymerization was prevented by an inhibitory tetrapeptide. Glycine-ethyl ester and a glutamine residue of a synthetic dodecapeptide served as acyl acceptor and acyl donor transglutaminase substrates, respectively. The amount of ammonia released during the reaction was monitored using glutamate dehydrogenase and NADPH. Results: The use of a new glutamine substrate and optimization of activator and substrate concentrations increased sensitivity. Substitution of NADPH for NADH and introduction of an appropriate blank eliminated systemic overestimation of FXIII activity. The recovery of FXIII was 96%, the assay was linear up to 470 U/L, the detection limit was 1 U/L, and the imprecision (CV) was <8% even at very low FXIII activities. A reference interval of 108 -224 U/L (69 -143%) was estab-
Blood coagulation factor XIII (FXIII) 4 is a pro-transglutaminase of tetrameric structure (A 2 B 2 ) consisting of two potentially active A subunits (FXIII-A) and two inhibitory/protective B subunits (FXIII-B). In the terminal phase of the clotting cascade, FXIII is transformed into an active transglutaminase (FXIIIa) by the concerted action of thrombin and Ca 2ϩ . Thrombin cleaves an activation peptide from the N-terminal end of FXIII-A, and in the presence of Ca 2ϩ , FXIII-B then dissociates and FXIII-A assumes an enzymatically active configuration [for a review, see Ref. (1 ) ]. Transglutaminase (protein-glutamine:amine ␥-glutamyltransferase; EC 2.3.2.13) catalyzes an acyl transfer reaction in which the carboxamide group of a peptide-bound glutamine residue is the acyl donor and an appropriate primary amine is the acyl acceptor (2) (3) (4) . In the first step of the modified doubledisplacement reaction, the glutamine residue forms a thioester with the active site cysteine and ammonia is released. In the second step, the acyl group is transferred to the acyl acceptor amine and the amine is linked to the glutamine residue via a peptide (isopeptide) bond. When the acyl acceptor primary amine is provided by a peptide-
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bound lysine residue, the end result of the transglutaminase action is the cross-linking of two polypeptide chains.
The main physiological functions of FXIII are the cross-linking of fibrin and the covalent incorporation of ␣ 2 -plasmin inhibitor (␣ 2 -PI), the main physiological inhibitor of the fibrinolytic enzyme, plasmin, into fibrin polymers (4 ) . This way FXIII mechanically stabilizes fibrin and protects it from immediate elimination by the powerful fibrinolytic system. Fibrin cross-linking occurs through dimerization of ␥ chains and the formation of highly cross-linked ␣-chain polymers. ␣ 2 -PI provides a single glutamine residue, the penultimate N-terminal Gln, to the cross-linking reaction and becomes attached to lysine residues of fibrin ␣ chains.
FXIII is essential for maintaining hemostasis (5, 6 ) . Patients with inherited FXIII deficiencies exhibit severe bleeding diathesis and, in most cases, require life-long supplementation therapy. In addition, FXIII is also involved in maintaining pregnancy and in wound healing. Acquired FXIII deficiency may occur in several diseases, including inflammatory bowel diseases and acute leukemia. Increased plasma FXIII activity has been reported in patients with obliterative atherosclerosis (7 ) and diabetic angiopathy (8 ) , and in chronic leukemia patients with increased megakaryocytic activity (9 ) . Recently, a polymorphism of the FXIII A subunit, a Val-to-Leu transformation at position 34 in the activation peptide (10 ) , has been associated with a protective effect against occlusive vascular diseases (11 -13 ) .
A kinetic FXIII assay based on the continuous monitoring of ammonia released during the transglutaminase reaction was developed in our laboratory (14 ) and later modified by Fickenscher et al. (15 ) . In this method, ammonia released during the transglutaminase reaction is measured by a glutamate dehydrogenase (GluDH) indicator reaction. A diagnostic method (Berichrom ® FXIII) based on this assay has been manufactured and commercialized by Dade Behring. Although the kinetic assay is rapid and easy to adapt to clinical chemistry analyzers, its restricted linearity (16 ) , relatively low sensitivity, and frequent overestimation of FXIII concentrations in patients with severe FXIII deficiency (unpublished observation) prompted us to improve and optimize the assay.
Materials and Methods materials
All chemicals used in the study were of analytical grade and were obtained from Sigma, except for the NADPH and beef liver GluDH, which were from Roche. Standard Human Plasma, Control Plasma-N, and Control Plasma-P are products of Dade Behring. Bovine thrombin (17 ) and highly purified human plasma FXIII (18 ) were prepared in our laboratory. The dodecapeptide, corresponding to the N-terminal sequence of ␣ 2 -PI [␣ 2 -PI(1-12)] and the fibrin polymerization inhibitor tetrapeptide, Gly-Pro-ArgPro-amide (GPRP) (19 ) were prepared by the solid-phase method of Merrifield (20 ) with the use of Boc protective groups on a peptide synthesizer (AB 431A; PE Biosystems). The final deprotection was achieved by hydrofluoric acid treatment. The crude product was purified by preparative HPLC (Shimadzu) and lyophilized. The purities of both purified peptides were estimated to be Ͼ99% by analytical HPLC and mass spectrometry (Finnigan). 
plasma samples
Blood samples were collected after overnight fasting; 9 volumes of blood were drawn into Vacutainer Tubes (Becton Dickinson) containing 1 volume of 0.105 mol/L buffered sodium citrate. Platelet-poor plasma was obtained by centrifugation (2500g for 20 min at 20°C). Plasma was removed and, if not analyzed immediately, stored at Ϫ70°C. To monitor the stability of FXIII in plasma, five plasma samples were tested after storage at room temperature (22°C), and at 4, Ϫ20, and Ϫ70°C for up to 6 months. For linearity determinations, Standard Human Plasma (Dade Behring) was supplemented with a 1/50th volume of concentrated purified plasma FXIII preparation of known specific activity. The FXIII activities (U/L) of the nonsupplemented plasma, the supplemented plasma, and its dilutions were determined. Dilutions were made with physiological saline or with FXIII-deficient plasma with no detectable FXIII activity. In the linear range, the measured activities of the dilutions of the supplemented plasma corresponded to the activities calculated from the assayed values and respective volumes of Standard Human Plasma and purified FXIII. The assigned FXIII% value of Standard Human Plasma (100%) was used to calculate the FXIII% value of the supplemented plasma. For interference studies, five human plasmas from healthy subjects were supplemented with various concentrations of bilirubin (up to 200 mol/L) or triglycerides (up to 10 mmol/L). reagent composition and assay protocol The concentrations of the above components in the final reaction mixture were somewhat less, ϳ91% of reagent concentrations. ADP was required to obtain optimal stimulation of GluDH above pH 7.0 and to prevent its inhibition by excess substrates and by inhibitory plasma constituents. Blanks routinely contained 1 mmol/L iodoacetamide, a transglutaminase inhibitor. In addition, 20 mmol/L EDTA and 40 kilounits/L hirudin, inhibitors of FXIII activation, were also used in plasma blanks.
The absorbance was measured at 340 nm every 25 s up to 12.5 min. The linear interval of the reaction was determined using the KINSEARCH program of the analyzer, and the change in absorbance per minute was calculated according to the manufacturer's instructions (21 ) . Similar results were obtained when linear regression analysis was performed on measurement points between 5 and 10 min and the slope of the regression line was used for calculations. The values obtained for the blanks were subtracted, and the results were expressed as either U/L or as a percentage of the average normal (the mean of the reference group) plasma FXIII activity.
In experiments to optimize individual assay components, ␣ 2 -PI(1-12), Gly-O-Et, thrombin, CaCl 2 , and GluDH were used in various concentrations, as indicated below. For determination of the optimal thrombin concentration, thrombin was blocked at the end of the 5-min lag period by the addition of 40 kilounits/L hirudin. In experiments to determine the K M(app) for ␣ 2 -PI(1-12) and Gly-O-Et, highly purified plasma FXIII (25 mg/L in 100 mmol/L HEPES buffer, pH 7.7) was substituted for plasma in the assay mixture. In experiments testing the effect of ammonia present in the plasma or in reagent components, NH 4 Cl solution (up to 400 mol/L in HEPES buffer, pH 7.7) was substituted for plasma.
other methods
A new, highly sensitive sandwich ELISA was used to determine the concentration of FXIII in plasma (22 ) . In the ELISA, biotinylated monoclonal capture antibody against FXIII-B and peroxidase-labeled monoclonal detection antibody against FXIII-A were incubated with plasma dilutions in the wells of a streptavidin-coated microplate. The detection antibody-FXIII-capture antibody complex attached to the streptavidin-coated microplate was quantified by the measurement of peroxidase activity. Only the tetrameric plasma FXIII reacted in the assay; noncomplexed A or B subunits did not react. In some experiments, FXIII activity was also determined by the Berichrom F XIII method. In this case, the instructions of the manufacturer were followed meticulously. The FXIII-A Val34Leu polymorphism was identified by a PCR-restriction endonuclease method based on the amplification-created restriction site principle (23 ) .
statistical methods
The calibration curves for FXIII activity measurement methods were analyzed by weighted linear regression, using SPSS 7 for Windows software. The 1/SD 2 values of duplicate measurements of activities were used as statistical weights. The Kolmogorov-Smirnov test was used to compare the distribution of plasma FXIII activities in healthy individuals with the expected gaussian distribution (STATISTICA software; StatSoft). A reference interval was established according to the NCCLS guideline (24 ) . The test proposed by Dixon was used for the detection of potential outliers (25, 26 ) . The possibility that separate reference intervals would be required for male and female reference individuals was tested using the method of Harris and Boyd (24, 27 ) . The correlation between two methods was analyzed by Deming regression (28 ) using CBstat, a program written and kindly provided by Dr. K. Linnet. The program yields the straight line parameters with standard errors and the correlation coefficient, and checks for deviation from linearity. Error calculations were based on the jackknife principle (29 ) . Outliers deviating from the fitted line by more than 4 SD of the residuals were identified and excluded from the fit. Deviation of the intercept from zero was checked for significance with the Student t-test. Normalized values were also analyzed with a Bland-Altman plot (30 ) .
Results

assay principle
The assay involves the following three reactions: Activation of FXIII:
Transglutaminase reaction:
Indicator reaction:
Full activation of FXIII by thrombin and Ca 2ϩ occurs during the 5-min lag phase of the reaction. Fibrin polymerization is prevented by the tetrapeptide GPRP. It was also shown in separate experiments that under assay conditions, endogenous or contaminating ammonia up to 400 mol/L, i.e., up to 10-fold higher than the upper limit of the reference interval for ammonia in plasma, was consumed within 3 min. This was manifested by a sudden drop in the absorbance at 340 nm, which is used to measure the transformation of NADPH to NADP ϩ . In the absence of FXIII, no further change of absorbance occurred after this period.
The formed FXIIIa then cross-links the amine substrate Gly-O-Et to the substrate glutamine residue of ␣ 2 -PI(1-12), and ammonia is released. In the indicator reaction, ammonia is utilized for glutamate formation, and NADPH, the cofactor in the GluDH reaction, is transformed to NADP ϩ . NADPH consumption, measured by the decrease in the absorbance at 340 nm, is directly proportional to FXIII activity within a wide time window. Measurement of the change in absorbance between 5 and 10 min is recommended (Fig. 1) .
optimization of assay components
The optimal concentrations of activators were established. The dependence on Ca 2ϩ concentration followed a bellshaped curve characteristic of transglutaminases. The maximum was at 10 mmol/L CaCl 2 in the reagent, which corresponded to 9 mmol/L CaCl 2 in the final assay mixture ( Fig. 2A) . When optimizing the thrombin concentration, we paid special attention to the FXIII-A Val34Leu polymorphism. Recently, highly purified FXIII from different Val34Leu genotypes was used to demonstrate that thrombin cleaves the mutant Leu34 allele significantly faster than the wild-type Val34 allele (23, 31 ) . However, at full activation, the specific transglutaminase activity of FXIIIa was the same for the three FXIII Val34Leu genotypes (23 ) . was recommended in a previously described assay (15 ) . FXIIIa can deamidate peptide-bound substrate Gln residues in the absence of an amine substrate (1, 14 ) , which explains the substantial ammonia release at a Gly-O-Et concentration of 0 mmol/L, as shown in Fig. 3B . The presence of an amine substrate, in this case Gly-O-Et, produces a concentration-dependent increase of FXIIIa activity manifested by increased ammonia production. For the above reason, no Lineweaver-Burk plot was derived from the data, but the original saturation curve was fitted to a hyperbolic function plus a constant to take the residual activity into account. The fit shown in Fig. 3B yielded a K M(app) of 4.5 ϫ 10 Ϫ4 mol/L, and 5 mmol/L Gly-O-Et was indeed shown to be a saturating concentration. In the assay, 4 mmol/L ␣ 2 -PI(1-12) and 5 mmol/L Gly-O-Et were used routinely.
plasma blank
We attempted to obtain an appropriate plasma blank by preventing the activation of FXIII or by blocking the transglutaminase activity. These goals were achieved by inhibiting thrombin with hirudin, by chelating Ca 2ϩ , or by adding the transglutaminase inhibitor and -SH reactant, iodoacetamide. In all three cases, identical results were obtained; therefore, only the results with iodoacetamide are presented. We analyzed 341 samples from healthy individuals and patients for FXIII activity in the presence of iodoacetamide and found a FXIII-independent decrease of absorbance corresponding to a FXIII activity of 7.93 Ϯ 3.31 U/L (range, 2.6 -24.5 U/L). With 20 mmol/L EDTA or 40 kilounits/L hirudin, values for plasma blanks were 7.37 Ϯ 2.76 U/L and 7.01 Ϯ 2.02 U/L, respectively. The combination of these inhibitors of FXIII activation with each other or with iodoacetamide had no further influence on values obtained for plasma blanks.
When we did not subtract the values obtained for the blanks, FXIII activities measured with our assay were overestimated by 5%. In similar experiments using the Berichrom assay without an appropriate blank, we observed an 8% overestimation of FXIII activity. Table  1 demonstrates FXIII activity without and with correction using blanks in four FXIII-deficient patients (samples 1-4) and in two selected inpatients (samples 5 and 6) who had FXIII activity within the reference interval. FXIII activity Ͻ1% of the average normal (mean of the reference group) is considered a very severe hemorrhagic diathesis, whereas FXIII activity of 5-10% in most cases produces only a mild, if any, bleeding tendency. For both assays, it is clear that clinically misleading overestimation of FXIII activity in FXIIIdeficient patients would occur if the values obtained for the blanks were not subtracted. Without correction for the plasma blank, the Berichrom assay overestimated the FXIII activity in samples obtained from patients 5 and 6, who had FXIII activities within the reference interval, by as much as 27% and 22%. The overestimations with our assay were lower but still significant (14% and 16%).
recovery and interference
To investigate the recovery of FXIII in the assay, plasma samples were supplemented with highly purified FXIII of known activity. Comparison of the activities of supplemented and nonsupplemented plasma samples revealed that the recovery of FXIII activity in the assay was 96%. High plasma ammonia concentrations (Ͼ200 mol/L) led to considerable consumption of NADPH during the lag phase of the reaction, and in this case, we recommend that the sample be diluted and remeasured. Bilirubin up to 200 mol/L did not interfere with the assay (bias Ͻ2%). The addition of 200 mol/L bilirubin to the plasma produced only a minimal increase in the absorbance at 340 nm (70 milliabsorbance units in the 0.6-cm cuvette of the COBAS MIRA Plus). Bias was negligible up to 7.5 mmol/L triglycerides (Ͻ1%). At this concentration, hypertriglyceridemia produced an increase of 900 milliabsorbance units (340 nm, 0.6-cm pathlength) in the sample. At 10 mmol/L triglycerides, a 9.9% negative bias was observed.
linearity, analytical sensitivity, and detection limit Direct dilutions of FXIII-supplemented plasma in the range of 0 -300% of the average normal were used for the determination of linear range. FXIII activity was measured by the modified assay described above and, for comparison, by the Berichrom assay (Fig. 4) . Because dilutions with physiological saline or FXIII-deficient plasma gave similar results, only data obtained with physiological saline are shown in Fig. 4 . With our optimized assay, FXIII activity was linear up to 300% (468 U/L; slope Ϯ SD, 1.54 Ϯ 0.03; intercept, 6.20 Ϯ 2.24 U/L; S y͉x ϭ 6.83; r ϭ 0.999). In accordance with a previous report (15 ) , the Berichrom assay was nonlinear above a FXIII activity of 150%; even the point corresponding to 150% activity was slightly below the regression line. Among 200 subsequent clinical samples received for FXIII determination in our laboratory, the activities of 4 (2.1%) were Ͼ150% (234 U/L), but none exceeded 300% (468 U/L).
The slopes of the calibration curve for the modified photometric assay and for the Berichrom assay were 1.54 and 0.99, respectively. These results demonstrate that optimization of the assay and the use of new substrate produced a 1.5-fold increase in sensitivity. The detection limit of the optimized photometric assay was estimated to be 1 U/L.
precision and carryover
The within-run and day-to-day imprecision (CV) was determined on reconstituted lyophilized Standard Hu- Table  2 ). Because there are no commercially available lyophilized plasma preparations with FXIII activity Ͻ30% of the average normal, plasma samples were used for the determination of within-run imprecision in the low FXIII activity range. At FXIII activities Ͼ10% of the average normal, both the within-run and day-to-day CVs were Ͻ5%, and at FXIII activities as low as 3% (5.2 U/L), the within-run CV was still well below 10%. The carryover in the COBAS MIRA Plus analyzer was Ͻ1%.
sample stability
The FXIII activities in five plasma samples were determined before (mean, 161.3 U/L; range, 81.2-257.6 U/L) and after storage for various intervals up to 6 months. The plasma samples could be stored at room temperature for at least 24 h without loss of FXIII activity (98.6% recovery), and after storage for 3 days, the recovery was still 95.6%. At 4°C, FXIII remained stable for at least 3 days (98.5% recovery). With samples stored at Ϫ20 and Ϫ70°C, no change of FXIII activity could be observed during the whole test period (98.5% and 106.0% recovery after 6 months, respectively).
reference interval
The distribution of FXIII activity in the group of reference individuals is shown in Fig. 5 . The distribution did not differ significantly from the ideal gaussian distribution (d ϭ 0.084; P ϭ 0.272). After log-normal transformation, however, the fit became better (d ϭ 0.048; P ϭ 0.552). No outliers were detected, and a reference interval of 108 -224 U/L was established by the nonparametric method. Because laboratory test results of blood coagulation factor determinations are traditionally expressed as a percentage of the average normal (mean of the reference group), the reference interval was also calculated as a percentage. If we accepted the mean FXIII activity of reference sample group (156.7 U/L) as 100%, the reference interval was calculated to be 69 -143%. Mean FXIII activities of the male and female subgroups were 158.5 Ϯ 32.5 and 155.3 Ϯ 26.6 U/L, respectively. Partitioning of reference values according to gender was not justified by statistical tests. The z value (0.64) was well below the critical z* value (2.30). The ratio of SD values for the two subgroups (1.22) was Ͻ1.5.
comparison with immunoassay
Because there is no reference method or generally accepted method for measurement of FXIII activity, we selected a methodologically well-established FXIII ELISA (22 ) for comparison. Deming regression of FXIII activity vs FXIII concentration is shown in Fig. 6A . The deviation of the intercept from zero was not significant with the Student t-test (P Ͼ0.1). Deviation from linearity also was not significant. The plot of residuals also suggested a linear relationship between the results obtained with the two methods. To bring concentration and activity mea- 
Discussion
Methods for the measurement of FXIII activity can be based on two different principles. In amine incorporation assays, a fluorescent (32 ), radiolabeled (33, 34 ) , or biotinylated (35, 36 ) amine substrate is covalently attached to a protein by FXIIIa; protein-bound and free amines are then separated, and the protein-linked fraction is measured quantitatively. The amine incorporation methods, although highly sensitive, are rather cumbersome, timeconsuming, and difficult to standardize. Their reproducibility is relatively poor, the assays cannot be adapted to clinical chemistry analyzers, and the separation step excludes the possibility of a true kinetic assay. The other group of functional FXIII assays utilizes the measurement of ammonia released in the first step of the transglutaminase reaction. The use of a NAD(P)H-dependent GluDH indicator reaction for the measurement of ammonia made it possible to develop a true kinetic FXIII assay (14 ) . In the original assay, fibrinogen was removed by bentonite treatment of plasma before the assay, and ethylamine and a modified ␤-casein were used as acyl acceptor and acyl donor substrates, respectively. This assay was later improved by adding an inhibitory pentapeptide that prevents fibrin polymerization, by incorporating Gly-O-Et as amine substrate, and by replacing modified ␤-casein with a synthetic decapeptide that resembles the sequence around the substrate glutamine residue in ␤-casein (15 ) . This way the time-consuming fibrinogen absorption step was eliminated and a well-defined, easily standardizable glutamine donor substrate was introduced.
It turned out, however, that the modified assay still had problems. A major problem was the frequent overestimation of FXIII activity in the plasma of FXIII-deficient patients. Because relatively low concentrations (5-10%) of FXIII are sufficient to maintain hemostasis, such overestimation might have serious clinical consequences. In addition, the monitoring of replacement therapy of patients with severe FXIII deficiency requires accurate measurement of FXIII activity in the low activity range. It was suspected that the overestimation is the result of NADHconsuming reactions that are independent of the formation of ammonia and that such an overestimation is also present, but less evident, at higher activities. Indeed, using appropriate blanks, we found that the Berichrom assay overestimated FXIII activity by an average of 8%. The replacement of NADPH for NADH in our optimized assay helped somewhat but did not eliminate the problem. Data from four FXIII-deficient patients (Table 1) demonstrated that correction, using values obtained for blanks, is essential for clinically relevant results. The need to correct using values obtained for blanks was not restricted to the low activity range. In two selected patients with FXIII activity within the reference interval, the Berichrom assay overestimated FXIII activity by Ͼ20% when no correction was used. The statement that the measurement of a blank is not necessary with this assay (15 ) is hardly defensible.
To increase the sensitivity of the assay, a new glutamine substrate was synthesized and the assay components were optimized. The sequence of ␣ 2 -PI(1-12) dodecapeptide, NQEQVSPLTLLK, corresponds to the N-terminal sequence of ␣ 2 -PI, an excellent natural substrate of FXIIIa (37 ) . The Gln residue at position 2 serves as the acyl donor transglutaminase substrate site (38, 39 ) . When we used this substrate and optimized the concentrations of assay constituents, the sensitivity of the assay increased 1.5-fold and a detection limit as low as 1 U/L could be achieved. These changes made the measurement of low FXIII activities more reliable.
In light of the recent discovery that the Val34Leu polymorphism influences the rate at which activation peptide is released from FXIII-A and thus the thrombin sensitivity of FXIII activation (23, 31 ) , optimization of the thrombin concentration was of particular importance. Thrombin should be used in a concentration sufficient to fully activate all FXIII variants during the lag phase of the reaction, otherwise the activity of the Val34 wild type, which is less attractive for thrombin, would be underestimated. We found that 20 kU/L thrombin was sufficient. In theory, the different activation rates of Val34Leu FXIII genotypes could be the basis for identifying these genotypes by non-molecular genetics methods. However, because the retention times of the Val34 and Leu34 FXIII activation peptides are different in reversed-phase HPLC (23 ), developing a method based on this principle (40 ) seemed to be more feasible.
The Berichrom assay has a restricted linearity with a linearity limit close to the upper limit of the reference interval (15, 16 ) . By optimizing the method, we extended the linear range considerably, and very few pathological samples fall outside this extended range.
The reference interval of the optimized assay was determined according to NCCLS guidelines and was found to be 108 -224 U/L. This corresponds to 69 -143% of average normal FXIII activity. The interval obtained with the optimized assay corresponds well to the intervals (70 -130%, 70 -140%, and 73-155%) obtained in earlier studies using less rigorous criteria (14 -16 ) and to the reference interval (67-133%) of the antigenic plasma FXIII assay (22 ) . These results contradict the view that FXIII has a reference interval broader than the reference intervals for most of the clotting factors (41, 42 ) .
In conclusion, we extensively modified the kinetic photometric FXIII assay by introducing a new synthetic gluClinical Chemistry 46, No. 12, 2000 tamine substrate, by optimizing the concentration of the constituents of the assay system, by substituting NADPH for NADH, and by introducing a sample blank. These modifications improved sensitivity and markedly lowered the detection limit. The assay became more reliable, especially in the low FXIII activity range, and the linearity range was greatly extended. Good recovery of FXIII was obtained. The results correlated well with those obtained with an immunoassay specific for plasma FXIII. The reference interval for the assay was established. The assay was adapted to a clinical chemistry analyzer and performed well. It can be widely used for the diagnosis of inherited and acquired FXIII deficiencies and for measuring increased FXIII concentrations.
